APA (7th ed.) Citation

Foresta, A., Ojeda-Fernandez, L., Macaluso, G., Roncaglioni, M. C., Tettamanti, M., Fortino, I., . . . Baviera, M. (2023). Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes. Clinical therapeutics, 45(4), e115-e126. https://doi.org/10.1016/j.clinthera.2023.02.007

Chicago Style (17th ed.) Citation

Foresta, Andreana, Luisa Ojeda-Fernandez, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Olivia Leoni, Stefano Genovese, and Marta Baviera. "Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes." Clinical Therapeutics 45, no. 4 (2023): e115-e126. https://doi.org/10.1016/j.clinthera.2023.02.007.

MLA (9th ed.) Citation

Foresta, Andreana, et al. "Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes." Clinical Therapeutics, vol. 45, no. 4, 2023, pp. e115-e126, https://doi.org/10.1016/j.clinthera.2023.02.007.